Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Kromek reports strongest sales year to date

Kromek was awarded £22mln of contracts, the largest value ever won in a year.
Radiation detection technology
It won significant contracts in nuclear detection and medical imaging.

The radiation detection firm Kromek Group PLC (LON:KMK) reported the strongest product sales year to date with over £22mln of contracts, the largest value the company has ever been awarded.

Sales topped £8.3mln for the year ended April, up from £8.1mln reported last year, accounting for half of total revenues.

It won significant contracts in nuclear detection and medical imaging, two of the largest growth opportunities for the company.

The group was selected as the sole source supplier by the US Department of Defense agency, DARPA, to supply its D3S radiation detectors as part of the SIGMA programme in an agreement worth US$6mln (£4.55mln).

In the medical imaging sector, Kromek secured a five-year contract totalling US$12.6m (£9mln) with a long-standing customer in the bone mineral densitometry sector. 

Kromek said it continued to maintain its strong market position as a key supplier of cadmium zinc telluride (CZT) detection systems.

“The year was also significant because we were awarded over US$30mln (£22mln) of contracts during the period - the largest value of contracts ever won in a year - and we strengthened our relationships with our current customers,” said chief executive Arnab Basu.

But despite being the strongest product sales year to date, the group failed to push down losses. Pre-tax losses widened to £4.14mln from £3.14mln last year.

Adjusted earnings (EBITDA) came in at a loss of £2.4mln, compared to a loss of £1.6mln last year, due to further investment of £3.2mln in research costs preparation for expected demand.

But Basu remained unfazed and was confident about the group's expansion, he said it had made good progress in the delivery of its CZT-based product in Asia.

“The group's products continue to gain traction across the globe as Kromek deepens its relationships with long-term customers and expands its reach.”

With a strengthened order book and improved revenues, he said the group was confident going forward.

"What you’re seeing is just the tip of the iceberg," Basu told Proactive, highlighting the radiation detection contract with the US government worth US$1bln.

He said that the development of the technology meant the group was "making a real difference to the end user by either reducing cost or ease of use, and that’s going to give us growth that’s going to give shareholder value."

Regarding Brexit, Basu remaind optimistic and noted that a majority of revenues are in US dollars.

Shares stood at 25p.

Watch:Kromek sees huge opportunities in three markets

--UPDATES SHARE PRICE, CEO COMMENT--

View full KMK profile View Profile

Kromek Group PLC Timeline

Related Articles

Adult gamer
April 10 2018
Most video games are developed in English, but sales are global and that has created a business in translating games into local languages and cultures.
The D3S detector kit
April 20 2018
Kromek, formerly Durham Scientific Crystals, was incorporated in April 2003 to commercialise technology that had been developed in the Physics Department of Durham University over a period of some 20 years.
Tekcapital-Invention-Discovery-Network-(IDN)-June-2015_opt.jpg
February 08 2018
The firm has established connections with more than 4,000 universities in 160 countries enabling it to capture all of the intellectual property available

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use